Business Wire

Lenovo Group: Second Quarter Financial Results 2025/26

20.11.2025 00:45:00 CET | Business Wire | Press release

Share

Lenovo delivers record quarterly results, marking significant progress in hybrid AI

Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported record results for the second quarter of fiscal year 2025/26, with overall group revenue reaching an all-time high of US$20.5 billion, up 15% year-on-year. Adjusted net income[1] grew 25% year-on-year to US$512 million, and adjusted net income margin expanded to 2.5%, driven by higher revenues. Together, these reflect the strength of the Group’s operational performance as they exclude the impact of non-cash fair value loss on warrants, notional interest on convertible bonds, and other non-cash items.

The Group delivered double-digit year-on-year revenue growth across all main business groups and sales geographies. The AI-related revenue mix increased by 13 percentage points year-on-year, accounting for 30% of the Group’s total revenue this quarter. The growth was driven by high-double-digit revenue growth in AI Servers and triple-digit revenue growth in AI PCs, AI smartphones, and AI Services.

These results are a testament to the Group’s clear strategy, operational excellence, and relentless innovation, reflecting not only the strength of its business today but also the resilience of its unique ‘Global/Local’ model and the vision of a company built to lead in the AI era. With the initial wave of infrastructure build-out in the AI era, the trend is evolving toward a more human- and enterprise-centric phase, as large language models become commoditized and user priorities shift toward personalization and private domain. This evolution is unlocking new opportunities across devices, hybrid infrastructure, and tailored solutions, and enabling the Group to expand its leadership in Personal AI and further deliver its value proposition in Enterprise AI.

As the macroeconomic environment stabilizes, Lenovo remains committed to executing its Hybrid AI strategy and investing in innovation to deliver sustainable long-term returns to shareholders and make AI truly personalized.

Lenovo’s Board of Directors declared an interim dividend of 8.50 HK cents per share.

Chairman and CEO quote – Yuanqing Yang:

“Capitalizing on the AI democratization trend, and thanks to our clear strategy, operational excellence and relentless innovation, Lenovo delivered another quarter of record performance, while making important progress in both Personal AI and Enterprise AI. We will continue to leverage our unique Global/Local model to navigate uncertainties and capture the tremendous Hybrid AI opportunities, and in doing so not only deliver sustainable long-term returns to our shareholders, but also make AI truly personalized for every individual and every enterprise.”

Financial Highlights:

 

Q2 FY 25/26
US$ millions

Q2 FY 24/25
US$ millions

Change

 

 

Group Revenue

20,452

17,850

15%

 

Net Income (profit attributable to equity holders)

340

359

(5%)

 

Adjusted Net Income (profit attributable to equity holders – non-HKFRS) [1]

512

409

25%

 

 

Basic earnings per share (US cents)

2.77

2.92

(5%)

 

Personal AI: Innovation strengthened market leadership, enriching ecosystem

Lenovo is meeting growing consumer demand for hyper-personalization with its Personal AI strategy, ‘One Personal AI, Multiple Devices’. Launching globally at Tech World on January 6, 2026, Lenovo’s Personal AI super agent will seamlessly orchestrate across wearable and ambient devices to perceive, learn, and act like its user - ultimately becoming a true Personal AI Twin.

Intelligent Devices Group (IDG) as the core engine for Lenovo’s Personal AI strategy, delivered strong Q2 FY25/26 results:

  • Overall IDG revenue grew nearly 12% year-on-year to US$15.1 billion.
  • PC market leadership was strengthened with a record 25.6% market share, further widening the lead over the number two player.
  • The PCs and smart devices business maintained its industry-leading profitability, driven by solid performance from high-margin segments.
  • AI PC penetration accelerated, accounting for 33% of all Lenovo PC shipments. Lenovo ranks #1 globally in the Windows AI PC segment with a 31.1% market share. Motorola smartphones delivered record volumes.
  • AI device momentum is particularly encouraging, with revenue mix from AI devices up 17 points year-on-year to 36%.

Enterprise AI: Unleashing Hybrid AI Advantage, from infrastructure to solutions and services

Lenovo is advancing its Enterprise AI strategy to help customers turn data and knowledge into actionable insights and value. The Group is well-positioned to drive Enterprise AI transformation and develop an AI Twin for customers. The shift from cloud-based AI training to on-premises and edge inferencing is expected to fuel greater growth in AI devices and AI applications, further expanding the company’s total addressable market.

Infrastructure Solutions Group (ISG) as the key driver of Lenovo’s hybrid infrastructure, delivered strong growth in Q2 FY25/26:

  • Revenue grew 24% year-on-year to US$4.1 billion through the continued strong execution of its CSP (Cloud Service Provider) and Enterprise SMB dual strategy.
  • CSP business delivered record fiscal Q2 revenue.
  • The AI infrastructure business revenue achieved high double-digit year-on-year growth with a strong pipeline.
  • Revenue from industry-leading liquid cooling solutions grew 154% year-on-year.
  • By optimizing Enterprise SMB business models to better serve the distinct needs of enterprise and SMB customers, the Group is confident that the infrastructure business will return to profitable growth soon.

Solutions and Services Group (SSG) delivered solid growth in Q2 FY25/26, providing solutions and services for enterprises that leverage the Lenovo Hybrid AI Advantage:

  • SSG’s overall revenue grew 18% year-on-year to US$2.6 billion – marking 18 consecutive quarters of year-on-year revenue growth.
  • Operating margin was up 1.9 points year-on-year to over 22%.
  • Revenue from Support Services accelerated with double-digit year-on-year growth; Managed services and Projects and Solutions revenue mix was up 1 point year-on-year to almost 60% of SSG’s total revenue.
  • SSG is unleashing the power of Lenovo Hybrid AI Advantage, combining the AI factory, AI services, and the AI library of repeatable, scalable AI solutions for selected vertical industries and horizontal functions.

Corporate and ESG highlights

Achievements, announcements, and notable commitments over the past quarter include:

[1] Note on adjusted net income: Adjusted measure was defined as financial metric by excluding net fair value changes on financial assets at fair value through profit or loss, amortization of intangible assets resulting from mergers and acquisitions, impairment and write-off of intangible assets, dilution gain on interest in an associate, fair value change on derivative financial liabilities relating to warrants, and notional interest on convertible bonds; and the corresponding income tax effects, if any.

About Lenovo

Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

LENOVO GROUP

 

FINANCIAL SUMMARY

For the quarter ended September 30, 2025

(in US$ millions, except per share data)

 

 

 

Q2
FY25/26

Q2
FY24/25

Y/Y CHG

Revenue

 

 

20,452

17,850

15%

Gross profit

 

3,147

 

2,796

 

13%

Gross profit margin

 

 

15.4%

 

15.7%

 

(0.3) pts

Operating expenses

 

 

(2,504)

 

(2,145)

 

17%

R&D expenses
(included in operating expenses)

 

(581)

 

 

(548)

 

6%

Expenses-to-revenue ratio

 

 

12.2%

 

12.0%

 

0.2 pts

Operating profit

 

 

643

 

651

 

(1)%

Other non-operating income/(expenses) – net

 

(149)

(178)

 

(16)%

Profit before taxation

 

 

494

 

473

 

4%

Taxation

 

 

(114)

 

(90)

 

27%

Profit for the period

 

 

380

 

383

 

(1)%

Non-controlling interests

 

 

(40)

 

(24)

 

62%

Net Income

(Profit attributable to equity holders)

 

 

340

359

 

 

(5)%

Adjusted Net Income

(Profit attributable to equity holders – non-HKFRS)[1]

 

512

409

 

25%

Earnings per share (US cents)
Basic
Diluted

 

 

2.77

2.52

 

2.92

2.78

 

(0.15)

(0.26)

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119867968/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye